Company

Rubius Therapeutics, Inc.

Cambridge, US biotech developing cell therapies from engineered red blood cells for cancer and autoimmune diseases.

About

Rubius Therapeutics develops Red Cell Therapeutics, genetically engineered red blood cells aimed at cancer and autoimmune diseases, with lead candidates RTX-240 and RTX-224. Founded in 2014 and based in Cambridge, US, it raised USD 200.00 mn in a Private Placement/Follow on on March 16, 2021, and was valued at USD 1.6 bn after its IPO in July 2017. It has completed 5 deals. Stage: Series C.

3Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in